ScripAkeso apparently disagreed with investors’ reactions after the Chinese biotech on 25 April provided an early release of preliminary overall survival (OS) data from an interim analysis of a high-stakes
ScripResults from a Phase III study in China of Akeso and Summit Therapeutics’ ivonescimab in non-small cell lung cancer (NSCLC) are an encouraging sign for the PD-1/VEGF-targeting bispecific antibody’s pi
ScripSummit Therapeutics and its partner Akeso have a commanding lead in the VEGF x PD-(L)1 bispecific cancer immunotherapy field, but BioNTech is also focused on being a major contender. Several key clini
ScripBioNTech made its name and fortune with its Pfizer-partnered COVID-19 vaccine, Comirnaty, but this year could be a turning point in its bid to diversify and become a major oncology company as well. Th